在一项多样化的尸检研究中,Apolipoprotein E和阿尔茨海默病的病理学
Claudia K Suemoto1, Regina Paradela1, Renata E P Leite1
1Division of Geriatrics, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.
Alzheimer's & dementia : the journal of the Alzheimer's Association
|November 21, 2025
概括
在巴西人中,Apolipoprotein E ε4 (APOE ε4) 等位基因增加了阿尔茨海默病 (AD) 的风险和病理学. APOE ε2/εX等位基因具有保护性,而APOE ε4/ε4透率因年龄而异.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 病理学 病理学 病理学
背景情况:
- 阿波蛋白E基因4 (APOE ε4) 是晚发性阿尔茨海默病 (AD) 的主要遗传风险因素.
- 大多数关于APOE ε4和AD风险的现有证据来自高收入国家的白人人口.
- 这项研究在多样化的巴西尸检队列中检查了APOE和AD病理.
研究的目的:
- 调查阿波利波蛋白E (APOE) 基因型与阿尔茨海默病 (AD) 病理学之间的关联.
- 评估APOE ε4和APOE ε2等位基因对多民族人群中AD神经病理负担的影响.
- 为了确定APOE-AD协会是否在巴西的种族群体之间存在差异.
主要方法:
- 利用了来自老龄化研究生物库 (BAS) 的数据,以横截面设计.
- 通过使用既定标准 (Braak,CERAD,Thal) 评估了AD病理.
- 从血液或脑组织中确定APOE基因型,并使用调整为人口因素的回归模型分析关联,测试种族相互作用.
主要成果:
- APOE ε4显示AD病理负担和诊断几率的剂量依赖性增加.
- APOE ε2/εX基因型显示出对AD病理的保护作用.
- APOE ε4/ε4在所有年龄组中都没有表现出完全的透性,白人和黑人之间存在一致的关联.
结论:
- APOE ε4显著增加了巴西人口的AD神经病理负担.
- APOE ε2/εX提供了对AD病理的保护.
- APOE和AD病理学之间的强烈关联在种族群体之间是一致的,证据扩展到高收入国家之外.
更多相关视频
07:08A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
8.2K
08:25Detecting Amyloid-β Accumulation via Immunofluorescent Staining in a Mouse Model of Alzheimer's Disease
Published on: April 19, 2021
3.9K
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
772
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
772
